Reply to "Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+breast cancer"

被引：0
|
作者：
Cao, Lifen [1 ]
Stabellini, Nickolas [2 ]
Amin, Amanda L. [3 ]
Montero, Alberto J. [1 ]
机构：
[1] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Med Ctr,Dept Med,Div Hematol & Oncol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[3] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Med Ctr,Dept Surg,Div Surg Oncol, Cleveland, OH 44106 USA
来源：
CANCER | 2022年 / 128卷 / 16期
关键词：
D O I：
10.1002/cncr.34339
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3130 / 3130
页数：1
相关论文
共 50 条
  • [1] Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+breast cancer
    Altundag, Kadri
    CANCER, 2022, 128 (16) : 3129 - 3129
  • [2] A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+breast cancer: A National Cancer Database analysis
    Cao, Lifen
    Towe, Christopher W.
    Shenk, Robert
    Stabellini, Nickolas
    Amin, Amanda L.
    Montero, Alberto J.
    CANCER, 2022, 128 (13) : 2433 - 2440
  • [3] Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+breast cancer: a National Cancer Database analysis
    Cao, Lifen
    Shenk, Robert
    Stabellini, Nickolas
    Miller, Megan E.
    Towe, Christopher W.
    Montero, Alberto J.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (01) : 169 - 176
  • [4] Prognostic Impact of Interval Breast Cancer Detection in Women with pT1aN0M0 Breast Cancer with HER2-positive Status: Results from a Multicenter Population-based Cancer Registry Study
    Boggiani, D.
    Sikokis, A.
    Rimanti, A.
    Pellegrino, B.
    Silini, E. M.
    Campanini, N.
    Barbieri, E.
    Cortesi, L.
    Panebianco, M.
    Porzio, R.
    Frassoldati, A.
    Sgargi, P.
    Falcini, F.
    Michiara, M.
    Musolino, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study
    Musolino, A.
    Sikokis, A.
    Boggiani, D.
    Rimanti, A.
    Pellegrino, B.
    Silini, E. M.
    Campanini, N.
    Barbieri, E.
    Cortesi, L.
    Panebianco, M.
    Porzio, R.
    Frassoldati, A.
    Sgargi, P.
    Falcini, F.
    Michiara, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Upfront Surgery versus Neoadjuvant Chemotherapy in cT1N0 HER2+Breast Cancer
    Huang, Kai
    Jakub, James
    Gabriel, Emmanuel
    Moreno-Aspitia, Alvaro
    McLaughlin, Sarah
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 2) : S483 - S484
  • [7] Follow-up of Patients Treated for pT1aN0M0 Breast Cancer: 10-year Survival and Prognostic Factors
    Crochet, Patrice
    Molinari, Nicolas
    Darmon, Jean-Claude
    Cutuli, Bruno
    Serin, Daniel
    BREAST JOURNAL, 2016, 22 (03): : 363 - 365
  • [8] HER2/NEU OVEREXPRESSION IN pT1a OR pT1b, N0, M0 BREAST CANCER
    Petroni, S.
    Asselti, M.
    Giotta, F.
    Quero, C.
    D'Amico, C.
    Marzano, A. L.
    Daprile, R.
    Salvatore, C.
    Colucci, G.
    Simone, G.
    CANCER TREATMENT REVIEWS, 2010, 36 : S103 - S103
  • [9] Does T1c-2N0-1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
    Zhang, Jie
    Yu, Yushuai
    Chen, Weiwei
    Fu, Wenfen
    Chen, Ruiliang
    Yi, Jialu
    Song, Chuangui
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis
    Lifen Cao
    Robert Shenk
    Nickolas Stabellini
    Megan E. Miller
    Christopher W. Towe
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2022, 191 : 169 - 176
12345